Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.26355/eurrev_202007_21923 http://scihub22266oqcxt.onion/10.26355/eurrev_202007_21923 32706091!ä!32706091 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Eur+Rev+Med+Pharmacol+Sci 2020 ; 24 (13): 7506-7511 Nephropedia Template TP {{tp|p=32706091|t=2020. Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 |pdf=|usr=}}{{32706091}} gab.com Text Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 JO: Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32706091 #FOAvip OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic mainly involves respiratory symptoms, though gastrointestinal (GI) symptoms are increasingly being recognized. In this context, the presence of comorbidities appears to be associated with adverse outcomes. However, the role of digestive manifestations is not yet well defined. The primary aim of this study was to assess the prevalence of GI symptoms and digestive comorbidities in a cohort of patients with COVID-19 compared to controls. The secondary aim was to determine the association of GI-symptoms and digestive comorbidities with clinical outcomes. PATIENTS AND METHODS: Inpatients with COVID-19 and controls with similar symptoms and/or radiological findings were enrolled. Symptoms at admission and throughout hospitalization were collected as they were comorbidities. The measured clinical outcomes were mortality, intensive care unit admission and cumulative endpoint. RESULTS: A total of 105 patients were included: 34 with COVID-19 and 71 controls. At admission, the prevalence of GI symptoms among COVID-19 patients was 8.8%. During hospitalization, the frequency of GI symptoms was higher in patients with COVID-19 than in controls (p=0.004). Among patients with COVID-19, the mortality and a cumulative endpoint rates of those with GI symptoms were both lower than for those without GI symptoms (p=0.016 and p=0.000, respectively). Finally, we found digestive comorbidities to be associated with a milder course of COVID-19 (p=0.039 for cumulative endpoint). CONCLUSIONS: Our results highlighted the non-negligible frequency of GI symptoms in patients with COVID-19, partly attributable to the therapies implemented. In addition, the presence of GI symptoms and digestive comorbidities is associated with better outcomes. Most likely, digestive comorbidities do not hinder the host's immune response against SARS-COV-2, and the occurrence of GI symptoms might be linked to a faster reduction of the viral load via the faecal route. Twit Text FOAVip Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 ????Eur Rev Med Pharmacol Sci http://www.kidney.de/pget.php?&tw=1&pmid=32706091 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32706091 #FOAvip English Wikipedia <ref>{{Cite pmid|32706091}}</ref> Gastrointestinal symptoms and digestive comorbidities in an Italian cohort of patients with COVID-19 #MMPMID32706091 Papa A; Covino M; Pizzolante F; Miele L; Lopetuso LR; Bove V; Iorio R; Simeoni B; Vetrone LM; Tricoli L; Mignini I; Schepis T; D'Alessandro A; Coppola G; Nicoletti T; Visconti E; Rapaccini G Eur Rev Med Pharmacol Sci 2020[Jul]; 24 (13): 7506-7511 PMID32706091show ga OBJECTIVE: The Coronavirus Disease 2019 (COVID-19) pandemic mainly involves respiratory symptoms, though gastrointestinal (GI) symptoms are increasingly being recognized. In this context, the presence of comorbidities appears to be associated with adverse outcomes. However, the role of digestive manifestations is not yet well defined. The primary aim of this study was to assess the prevalence of GI symptoms and digestive comorbidities in a cohort of patients with COVID-19 compared to controls. The secondary aim was to determine the association of GI-symptoms and digestive comorbidities with clinical outcomes. PATIENTS AND METHODS: Inpatients with COVID-19 and controls with similar symptoms and/or radiological findings were enrolled. Symptoms at admission and throughout hospitalization were collected as they were comorbidities. The measured clinical outcomes were mortality, intensive care unit admission and cumulative endpoint. RESULTS: A total of 105 patients were included: 34 with COVID-19 and 71 controls. At admission, the prevalence of GI symptoms among COVID-19 patients was 8.8%. During hospitalization, the frequency of GI symptoms was higher in patients with COVID-19 than in controls (p=0.004). Among patients with COVID-19, the mortality and a cumulative endpoint rates of those with GI symptoms were both lower than for those without GI symptoms (p=0.016 and p=0.000, respectively). Finally, we found digestive comorbidities to be associated with a milder course of COVID-19 (p=0.039 for cumulative endpoint). CONCLUSIONS: Our results highlighted the non-negligible frequency of GI symptoms in patients with COVID-19, partly attributable to the therapies implemented. In addition, the presence of GI symptoms and digestive comorbidities is associated with better outcomes. Most likely, digestive comorbidities do not hinder the host's immune response against SARS-COV-2, and the occurrence of GI symptoms might be linked to a faster reduction of the viral load via the faecal route. |Aged[MESH] |Aged, 80 and over[MESH] |Antiviral Agents/*pharmacology[MESH] |Betacoronavirus/*drug effects[MESH] |COVID-19[MESH] |Case-Control Studies[MESH] |Cohort Studies[MESH] |Comorbidity[MESH] |Coronavirus Infections/diagnosis/*drug therapy/epidemiology[MESH] |Female[MESH] |Gastrointestinal Diseases/diagnosis/*drug therapy/epidemiology[MESH] |Humans[MESH] |Italy[MESH] |Male[MESH] |Microbial Sensitivity Tests[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Pneumonia, Viral/diagnosis/*drug therapy/epidemiology[MESH] |Prospective Studies[MESH]Gastrointestinal symptoms and digestive comorbidities in an Italian co(epmc).pdf DeepDyve Pubget Overpricing